CompletedPhase 2NCT01623869
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Sandra D'Angelo, PhDAlliance for Clinical Trials in Oncology
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2015
Study locations (30)
- Beebe Medical Center, Lewes, Delaware, United States
- Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
- Washington Hospital Center, Washington D.C., District of Columbia, United States
- Oncare Hawaii Inc-POB II, Honolulu, Hawaii, United States
- Queen's Medical Center, Honolulu, Hawaii, United States
- Straub Clinic and Hospital, Honolulu, Hawaii, United States
- University of Hawaii Cancer Center, Honolulu, Hawaii, United States
- Oncare Hawaii Inc-Kuakini, Honolulu, Hawaii, United States
- Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States
- Castle Medical Center, Kailua, Hawaii, United States
- Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States
- Oncare Hawaii Inc-Pali Momi, ‘Aiea, Hawaii, United States
- Pali Momi Medical Center, ‘Aiea, Hawaii, United States
- Saint Joseph Medical Center, Bloomington, Illinois, United States
- Illinois CancerCare-Bloomington, Bloomington, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01623869 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive